Lord, Abbett & Co
DNTH icon

Lord, Abbett & Co’s Dianthus Therapeutics DNTH Stock Holding History

Lord, Abbett & Co’s Portfolio DNTH Stock Details DNTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$25.1M Buy
+299,210
New +$17.3M 0.08% 244

Other funds holding DNTH

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Lord, Abbett & Co's DNTH Position: Q1 2026 in Review

Lord, Abbett & Co opened a new position in Dianthus Therapeutics (DNTH) in Q1 2026: 299,210 shares worth $25.1M. The stake represents 0.08% of the portfolio and ranks #244 among its holdings.

241 funds tracked by Wall St. Rank hold DNTH as of Q1 2026.

  • Lord, Abbett & Co held 299,210 shares of Dianthus Therapeutics worth $25.1M as of Q1 2026.
  • Dianthus Therapeutics was a new Lord, Abbett & Co position in Q1 2026.
  • Dianthus Therapeutics made up 0.08% of Lord, Abbett & Co's portfolio in Q1 2026, its #244 holding.
  • 241 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q1 2026.

Based on Lord, Abbett & Co's 13F filing for Q1 2026, filed 14 May 2026.